Application of Bacteriophages in Common Infectious Diseases of the Oral Cavity
-
摘要: 噬菌体具有感染和杀死细菌的能力，现已应用于多种口腔疾病中，为口腔疾病的防治提供新思路，并有望成为治疗口腔疾病的新型生物抗菌剂。从噬菌体的概念及应用前景、4种口腔常见感染性疾病及其致病菌、现有治疗方法、噬菌体在该疾病中的应用和展望等6个方面综述噬菌体在口腔医学中的应用，为临床上开展噬菌体疗法奠定理论依据。Abstract: Bacteriophages possess the ability to infect and kill bacteria and have now been applied in various oral diseases, providing new insights for the prevention and treatment of oral diseases. They are expected to become a novel biological antibacterial agent for treating oral diseases. This paper comprehensively discusses the application of bacteriophages in oral medicine from six aspects: the concept and application prospects of bacteriophages, four common infectious diseases of the oral cavity and their pathogenic bacteria, existing treatment methods, and the application and outlook of bacteriophages in these diseases. Lay a theoretical basis for the clinical implementation of phage therapy.
-
Key words:
- Bacteriophage /
- Phage therapy /
- Stomatology /
- Infectious diseases
-
[1] 陈晶. 口腔健康 全身健康[N]. 人民政报,2022-09-14(007). [2] Chen X,Wei Y,Ji X. Research progress of prophages[J]. Yi Chuan,2021,43(3):240-248. [3] Roughgarden J. Lytic/lysogenic transition as a life-history switch[J]. Virus Evol,2024,10(1):veae028. [4] Mertz L. Phage therapy takes on broad applications[J]. IEEE Pulse,2022,13(5):9-15. doi: 10.1109/MPULS.2022.3208823 [5] Liu Z,Zhang Z J,He K T,et al. Research progress on the effects of the interactions between phage and periodontal pathogens on periodontal disease[J]. Zhonghua Kou Qiang Yi Xue Za Zhi,2021,56(12):1282-1286. [6] Chang R Y K,Wallin M,Lin Y,et al. Phage therapy for respiratory infections[J]. Adv Drug Deliv Rev,2018,133(8):76-86. [7] Dery K J,Górski A,Międzybrodzki R,et al. Therapeutic perspectives and mechanistic insights of phage therapy in allotransplantation[J]. Transplantation,2021,105(7):1449-1458. doi: 10.1097/TP.0000000000003565 [8] de Vries C R,Chen Q,Demirdjian S,et al. Phages in vaccine design and immunity; mechanisms and mysteries[J]. Curr Opin Biotechnol,2021(4)68: 160-165. [9] Hsu B B,Gibson T E,Yeliseyev V,et al. Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model[J]. Cell Host Microbe,2019,25(6):803-814. doi: 10.1016/j.chom.2019.05.001 [10] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global,regional,and national incidence,prevalence,and years lived with disability for 354 diseases and injuries for 195 countries and territories,1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet,2018,392(10):1789-1858. [11] Zhang J,Xu X. Research progress in the relationship between lactobacillus and dental caries[J]. Si Chuan Da Xue Xue Bao Yi Xue Ban,2022,53(5):929-934. [12] Cui T,Luo W,Xu L,et al. Progress of antimicrobial discovery against the major cariogenic pathogen streptococcus mutans[J]. Curr Issues Mol Biol,2019,3(2):601-644. [13] Alsadat F A,El-Housseiny A A,Alamoudi N M,et al. Conservative treatment for deep carious lesions in primary and young permanent teeth[J]. Niger J Clin Pract,2018,21(12):1549-1556. doi: 10.4103/njcp.njcp_202_18 [14] Xu J,Yang H,Bi Y,et al. Activity of the Chimeric Lysin ClyR against common gram-positive oral microbes and its anticaries efficacy in rat models[J]. Viruses,2018,10(7):380. doi: 10.3390/v10070380 [15] Jiang W,Wang Y,Luo J,et al. Antimicrobial peptide GH12 prevents dental caries by regulating dental plaque microbiota[J]. Appl Environ Microbiol,2020,86(14):e00527-20. [16] Rajabi Z,Soltan Dallal M M,Afradi M R,et al. Comparison of the effect of extracted bacteriocin and lytic bacteriophage on the expression of biofilm associated genes in Streptococcus mutans[J]. Adv Mater Sci Eng,2022,22(2):1-7. [17] Ben-Zaken H,Kraitman R,Coppenhagen-Glazer S,et al. Isolation and characterization of Streptococcus mutans phage as a possible treatment agent for caries[J]. Viruses,2021,13(5):825. doi: 10.3390/v13050825 [18] Guo X,Wang X,Shi J,et al. A review and new perspective on oral bacteriophages: Manifestations in the ecology of oral diseases[J]. J Oral Microbiol,2024,16(1):2344272. doi: 10.1080/20002297.2024.2344272 [19] Ordinola-Zapata R,Noblett W C,Perez-Ron A,et al. Present status and future directions of intracanal medicaments[J]. Int Endod J,2022,55(3):613-636. [20] Georgiou A C,Crielaard W,Armenis I,et al. Apical periodontitis is associated with elevated concentrations of inflammatory mediators in peripheral blood: A systematic review and meta-analysis[J]. J Endod,2019,45(11):1279-1295. doi: 10.1016/j.joen.2019.07.017 [21] Tibúrcio-Machado C S,Michelon C,Zanatta F B,et al. The global prevalence of apical periodontitis: A systematic review and meta-analysis[J]. Int Endod J,2021,54(5):712-735. doi: 10.1111/iej.13467 [22] Rôças I N,Siqueira J F Jr. Frequency and levels of candidate endodontic pathogens in acute apical abscesses as compared to asymptomatic apical periodontitis[J]. PLoS One,2018,13(1):e0190469. doi: 10.1371/journal.pone.0190469 [23] Restrepo-Restrepo F A,Cañas-Jiménez S J,Romero-Albarracín R D,et al. Prognosis of root canal treatment in teeth with preoperative apical periodontitis: A study with cone-beam computed tomography and digital periapical radiography[J]. Int Endod J,2019,52(11):1533-1546. doi: 10.1111/iej.13168 [24] Liu S Q,Chen X,Wang X X,et al. Outcomes and prognostic factors of apical periodontitis by root canal treatment and endodontic microsurgery-a retrospective cohort study[J]. Ann Palliat Med,2021,10(5):5027-5045. doi: 10.21037/apm-20-2507 [25] Khalifa L,Brosh Y,Gelman D,et al. Targeting Enterococcus faecalis biofilms with phage therapy[J]. Appl Environ Microbiol,2015,81(8):2696-705. doi: 10.1128/AEM.00096-15 [26] Plumet L,Ahmad-Mansour N,Dunyach-Remy C,et al. Bacteriophage therapy for staphylococcus aureus infections: A review of animal models,treatments,and clinical trials[J]. Front Cell Infect Microbiol,2022,17(6):907314. [27] Lee D,Im J,Na H,et al. The novel enterococcus phage vB_EfaS_HEf13 has broad lytic activity against clinical isolates of Enterococcus faecalis[J]. Front Microbiol,2019,17(12):2877. [28] Voit M,Trampuz A,Gonzalez Moreno M. In vitro evaluation of five newly isolated bacteriophages against E. faecalis biofilm for their potential use against post-treatment apical periodontitis[J]. Pharmaceutics,2022,14(9):1779. doi: 10.3390/pharmaceutics14091779 [29] Xiang Y Y,Li W Y ,Song F,et al. Biological characteristics and whole-genome analysis of the Enterococcus faecalis phage PEf771[J]. Canadian Journal of Microbiology,2020,66 (9): 505-520. [30] Xiang Y Y,Ma C L ,Yin S,et al. Phage therapy for refractory periapical periodontitis caused by Enterococcus faecalis in vitro and in vivo[J]. Appl Microbiol Biotechnol,2022,106(5-6): 2121-2131. [31] Kwon T,Lamster I B,Levin L. Current concepts in the management of periodontitis[J]. Int Dent J,2021,71(6):462-476. doi: 10.1111/idj.12630 [32] Sanz M,Marco Del Castillo A,Jepsen S,et al. Periodontitis and cardiovascular diseases: Consensus report[J]. J Clin Periodontol,2020,47(3):268-288. doi: 10.1111/jcpe.13189 [33] Baeza M,Morales A,Cisterna C,et al. Effect of periodontal treatment in patients with periodontitis and diabetes: Systematic review and meta-analysis[J]. J Appl Oral Sci,2020,10(1):e20190248. [34] Dominy S S,Lynch C,Ermini F,et al. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors[J]. Sci Adv,2019,55(1):e3333. [35] Sanz M,Herrera D,Kebschull M,et al. EFP workshop participants and methodological consultants treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline[J]. J Clin Periodontol,2020,47(6):54-60. [36] Chen Z,Guo Z,Lin H,et al. The feasibility of phage therapy for periodontitis[J]. Future Microbiol,2021,16(1):649-656. [37] Kabwe M,Brown T L,Dashper S,et al. Genomic,morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting Fusobacterium nucleatum biofilms[J]. Sci Rep,2019,9(1):9107. doi: 10.1038/s41598-019-45549-6 [38] Tang-Siegel G G,Chen C,Mintz K P. Increased sensitivity of aggregatibacter actinomycetemcomitans to human serum is mediated by induction of a bacteriophage[J]. Mol Oral Microbiol,2023,38(1):58-70. doi: 10.1111/omi.12378 [39] Bhardwaj S B,Mehta M,Sood S,et al. Isolation of a novel phage and targeting biofilms of drug-resistant oral enterococci[J]. J Glob Infect Dis,2020,12(1):11-15. doi: 10.4103/jgid.jgid_110_19 [40] Kim M Y,Hyun I K,An S,et al. In vitro anti-inflammatory and antibiofilm activities of bacterial lysates from lactobacilli against oral pathogenic bacteria[J]. Food Funct,2022,13(24):12755-12765. doi: 10.1039/D2FO00936F [41] Berglundh T,Armitage G,Araujo M G,et al. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions[J]. J Clin Periodontol,2018,45(6):S286-S291. [42] Bao K,Li X,Poveda L,et al. Proteome and microbiome mapping of human gingival tissue in health and disease[J]. Front Cell Infect Microbiol,2020,2(10):588155. [43] Mulla M,Mulla M,Hegde S,et al. In vitro assessment of the effect of probiotic lactobacillus reuteri on peri-implantitis microflora[J]. BMC Oral Health,2021,21(1):408. doi: 10.1186/s12903-021-01762-2 [44] Schwarz F,Derks J,Monje A,et al. Peri-implantitis[J]. J Periodontol,2018,89(1):S267-S290. [45] Alves C H,Russi K L,Rocha N C,et al. Host-microbiome interactions regarding peri-implantitis and dental implant loss[J]. J Transl Med,2022,20(1):425. doi: 10.1186/s12967-022-03636-9 [46] Lin G H,Suárez López Del Amo F,Wang H L. Laser therapy for treatment of peri-implant mucositis and peri-implantitis: An American academy of periodontology best evidence review[J]. J Periodontol,2018,89(7):766-782. [47] Toledano M,Osorio M T,Vallecillo-Rivas M,et al. Efficacy of local antibiotic therapy in the treatment of peri-implantitis: A systematic review and meta-analysis[J]. J Dent,2021,113(11):103790. [48] Hashimoto K,Yoshinari M,Matsuzaka K,et al. Identification of peptide motif that binds to the surface of zirconia[J]. Dent Mater J,2011,30(6):935-940. doi: 10.4012/dmj.2011-161 [49] Hosseini Hooshiar M,Salari S,Nasiri K,et al. The potential use of bacteriophages as antibacterial agents in dental infection[J]. Virol J,2024,21(1):258. doi: 10.1186/s12985-024-02510-y [50] Rehman S,Ali Z,Khan M,et al. The dawn of phage therapy[J]. Rev Med Virol,2019,29(4):e2041. doi: 10.1002/rmv.2041 [51] Hatfull G F,Dedrick R M,Schooley R T. Phage therapy for antibiotic-resistant bacterial infections[J]. Annu Rev Med,2022,73(1):197-211. doi: 10.1146/annurev-med-080219-122208 -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 84
- HTML全文浏览量: 43
- PDF下载量: 1
- 被引次数: 0
